Abbott (NYSE:ABT)’s new Phase III Study showed that HUMIRA® (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn's disease who lost response to, or were intolerant to, infliximab (Remicade®) therapy.
Crohn's disease is a serious, chronic inflammatory disease of the gastrointestinal (GI) tract (affecting more than one million people in North America and Europe) that has no medical or surgical cure and only few options for management.
The said Phase III data has been simultaneously presented at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.
Source: Abbott Press Release
Comment Preview